Item Type | Name |
Concept
|
Kidney Glomerulus
|
Concept
|
Kidney Transplantation
|
Concept
|
Kidney Failure, Chronic
|
Concept
|
Acute Kidney Injury
|
Concept
|
Kidney
|
Concept
|
Kidney Diseases
|
Concept
|
Kidney Diseases, Cystic
|
Concept
|
Kidney Tubules
|
Concept
|
Kidney Function Tests
|
Academic Article
|
A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease.
|
Academic Article
|
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-2003. A 68-year-old woman with impaired renal function.
|
Academic Article
|
Strategies for preservation of ovarian and testicular function after immunosuppression.
|
Academic Article
|
New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences?
|
Academic Article
|
The role of kidney biopsy in the management of lupus nephritis.
|
Academic Article
|
Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease.
|
Academic Article
|
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
|
Academic Article
|
The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
|
Academic Article
|
Uncertainty in the treatment of anemia in chronic kidney disease.
|
Academic Article
|
Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database.
|
Academic Article
|
Correction of anemia with epoetin alfa in chronic kidney disease.
|
Academic Article
|
The target hemoglobin in patients with chronic kidney disease.
|
Academic Article
|
Anaemia of CKD--the CHOIR study revisited.
|
Academic Article
|
Anemia of chronic kidney disease: CHOIR and the FDA.
|
Academic Article
|
Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
|
Academic Article
|
Does correction of anemia slow the progression of chronic kidney disease?
|
Academic Article
|
Is it time to reconsider subcutaneous administration of epoetin?
|
Academic Article
|
Anemia of chronic kidney disease.
|
Academic Article
|
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.
|
Academic Article
|
The optimal hemoglobin in dialysis patients- a critical review.
|
Academic Article
|
Managing anemia in dialysis patients: hemoglobin cycling and overshoot.
|
Academic Article
|
Prevention of intravenous contrast-induced nephropathy in hospital inpatients.
|
Academic Article
|
Acute coronary syndrome in ESRD patients.
|
Academic Article
|
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease.
|
Academic Article
|
Pure red cell aplasia due to follow-on epoetin.
|
Academic Article
|
Iron deficiency in non-dialysis chronic kidney disease.
|
Academic Article
|
De novo multifocal renal cell carcinoma in the renal allograft.
|
Academic Article
|
Acute phosphate nephropathy.
|
Academic Article
|
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.
|
Academic Article
|
Hemoglobin target in chronic kidney disease: a pediatric perspective.
|
Academic Article
|
Does treatment with calcitriol improve survival in predialysis patients with chronic kidney disease?
|
Academic Article
|
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
|
Academic Article
|
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients.
|
Academic Article
|
The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
|
Academic Article
|
Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
|
Academic Article
|
Kidney pathological changes in metabolic syndrome: a cross-sectional study.
|
Academic Article
|
Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions.
|
Academic Article
|
Role of vitamin D in chronic kidney disease.
|
Academic Article
|
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
|
Academic Article
|
Posttransplant anemia: the role of sirolimus.
|
Academic Article
|
Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro.
|
Academic Article
|
Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
|
Academic Article
|
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
|
Academic Article
|
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.
|
Academic Article
|
Hypertension in the developing world: challenges and opportunities.
|
Academic Article
|
Does TREAT give the boot to ESAs in the treatment of CKD anemia?
|
Academic Article
|
Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study.
|
Academic Article
|
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
|
Academic Article
|
ESAs in dialysis patients: are you a hedgehog or a fox?
|
Academic Article
|
Rapidly deteriorating kidney function in a young man previously diagnosed with membranous nephropathy.
|
Academic Article
|
Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
|
Academic Article
|
Diabetes, anemia and CKD: Why TREAT?
|
Academic Article
|
Even in nephrology, gurudakshina is important.
|
Academic Article
|
Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
|
Academic Article
|
Anemia in chronic kidney disease: new advances.
|
Academic Article
|
Message to the FDA on ESAs: REMS is not enough, more studies are needed.
|
Academic Article
|
What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
|
Academic Article
|
Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
|
Academic Article
|
Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study.
|
Academic Article
|
Is there a deleterious effect of erythropoietin in end-stage renal disease?
|
Academic Article
|
ASN clinicopathologic conference.
|
Academic Article
|
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
|
Academic Article
|
Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents.
|
Academic Article
|
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
|
Academic Article
|
Sudden cardiac arrest in ESRD patients.
|
Academic Article
|
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
|
Academic Article
|
Chronic kidney disease in the Arab world: a call for action.
|
Academic Article
|
Frequency of and risk factors for poor cognitive performance in hemodialysis patients.
|
Academic Article
|
Metabolic syndrome and chronic kidney disease.
|
Academic Article
|
Con: Randomized controlled trials (RCT) have failed in the study of dialysis methods.
|
Academic Article
|
Pro: The value of randomized controlled studies in dialysis methods.
|
Academic Article
|
Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study.
|
Academic Article
|
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
|
Academic Article
|
Consanguinity in Saudi Arabia: a unique opportunity for pediatric kidney research.
|
Academic Article
|
Burden and predictors of hypertension in India: results of SEEK (Screening and Early Evaluation of Kidney Disease) study.
|
Academic Article
|
The case | Renal tubular acidosis and eye findings.
|
Academic Article
|
Cognitive function and all-cause mortality in maintenance hemodialysis patients.
|
Academic Article
|
Outcome of acute kidney injury in pediatric patients admitted to the intensive care unit.
|
Academic Article
|
Predictors of renal replacement therapy and mortality in children with chronic kidney disease.
|
Academic Article
|
Cause of Death in Patients With Diabetic CKD Enrolled in the?Trial to Reduce Cardiovascular Events With Aranesp Therapy?(TREAT).
|
Academic Article
|
Prevalence of Hyperparathyroidism, Mineral and Bone Disorders in Children with Advanced Chronic Kidney Disease.
|
Academic Article
|
The International Society of Nephrology (ISN) and the American Nephrologists of Indian Origin (ANIO) Online Clinical Nephropathology Certificate (CNC) program.
|
Academic Article
|
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
|
Academic Article
|
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type?2 Diabetic Patients With CKD.
|
Academic Article
|
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
|
Academic Article
|
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.
|
Academic Article
|
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
|
Academic Article
|
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
|
Academic Article
|
Recreational use of marijuana: Current experience and information for nephrologists.
|
Academic Article
|
Renal pathology practice globally: identifying needs and meeting the challenge.
|
Academic Article
|
Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
|
Academic Article
|
Occupational risk factors for chronic kidney disease in Andhra Pradesh: 'Uddanam Nephropathy'.
|
Academic Article
|
Multiparametric Cardiac Magnetic Resonance for Chronic Kidney Disease: Mapping the Footprints of a "Silent Killer"?
|
Academic Article
|
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
|
Academic Article
|
Empagliflozin in Patients with Chronic Kidney Disease.
|
Academic Article
|
Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply.
|
Academic Article
|
The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease.
|